News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
436,068 Results
Type
Article (20852)
Company Profile (103)
Press Release (415113)
Multimedia
Podcasts (12)
Webinars (7)
Section
Business (125850)
Career Advice (775)
Deals (21936)
Drug Delivery (34)
Drug Development (60749)
Employer Resources (54)
FDA (11388)
Job Trends (9157)
News (220269)
Policy (18431)
Tag
2024 BioCapital Digital (3)
2024 BioForest Digital (3)
2024 BioMidwest Digital (2)
2024 Biotech Bay Standard (7)
2024 Biotech Beach Digital (2)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (2)
2024 Genetown Standard (5)
2024 Lone Star Bio Digital (3)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (2)
2025 Lone Star Bio Digital (2)
2026 BioMidwest Elite (1)
2026 Bio NC Standard (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (1)
2026 Genetown Standard (1)
2026 Pharm Country Standard (2)
Academia (1508)
Accelerated approval (4)
Adcomms (16)
Allergies (67)
Alliances (30656)
ALS (72)
Alzheimer's disease (924)
Antibody-drug conjugate (ADC) (88)
Approvals (11411)
Artificial intelligence (185)
Autoimmune disease (22)
Automation (9)
Bankruptcy (163)
Best Places to Work (7772)
BIOSECURE Act (5)
Biosimilars (65)
Biotechnology (92)
Bladder cancer (71)
Brain cancer (27)
Breast cancer (219)
Cancer (1818)
Cardiovascular disease (107)
Career advice (654)
Career pathing (6)
CAR-T (135)
Cell therapy (361)
Cervical cancer (16)
Clinical research (50327)
Collaboration (585)
Compensation (291)
Complete response letters (15)
COVID-19 (1953)
CRISPR (28)
C-suite (180)
Cystic fibrosis (81)
Data (1806)
Decentralized trials (1)
Denatured (7)
Depression (27)
Diabetes (151)
Diagnostics (4066)
Digital health (13)
Diversity (5)
Diversity, equity & inclusion (17)
Drug discovery (71)
Drug pricing (24)
Drug shortages (2)
Duchenne muscular dystrophy (52)
Earnings (53329)
Editorial (12)
Employer branding (8)
Employer resources (53)
Events (70229)
Executive appointments (508)
FDA (12414)
Featured Employer (29)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (3)
Frontotemporal dementia (6)
Funding (510)
Gene editing (69)
Generative AI (15)
Gene therapy (202)
GLP-1 (386)
Government (2253)
Grass and pollen (3)
Guidances (28)
Healthcare (11870)
Huntington's disease (19)
IgA nephropathy (25)
Immunology and inflammation (103)
Indications (27)
Infectious disease (2073)
Inflammatory bowel disease (107)
Inflation Reduction Act (2)
Influenza (43)
Intellectual property (71)
Interviews (110)
IPO (11137)
IRA (11)
Job creations (1732)
Job search strategy (576)
Kidney cancer (10)
Labor market (7)
Layoffs (232)
Leadership (9)
Legal (3360)
Liver cancer (57)
Lung cancer (273)
Lymphoma (126)
Machine learning (6)
Management (20)
Manufacturing (170)
MASH (51)
Medical device (9689)
Medtech (9692)
Mergers & acquisitions (11185)
Metabolic disorders (396)
Multiple sclerosis (68)
NASH (11)
Neurodegenerative disease (61)
Neuropsychiatric disorders (13)
Neuroscience (1303)
NextGen: Class of 2025 (3784)
Non-profit (2133)
Northern California (2090)
Now hiring (4)
Obesity (193)
Opinion (105)
Ovarian cancer (66)
Pain (60)
Pancreatic cancer (70)
Parkinson's disease (97)
Partnered (14)
Patents (137)
Patient recruitment (94)
Peanut (42)
People (36524)
Pharmaceutical (18)
Pharmacy benefit managers (3)
Phase I (16240)
Phase II (22487)
Phase III (16544)
Pipeline (967)
Policy (41)
Postmarket research (1458)
Preclinical (5939)
Press Release (69)
Prostate cancer (76)
Psychedelics (21)
Radiopharmaceuticals (180)
Rare diseases (283)
Real estate (3401)
Recruiting (17)
Regulatory (14268)
Reports (22)
Research institute (1527)
Resumes & cover letters (133)
Rett syndrome (4)
RNA editing (1)
RSV (42)
Schizophrenia (45)
Series A (89)
Series B (63)
Sickle cell disease (33)
Southern California (1655)
Special edition (2)
Spinal muscular atrophy (111)
Sponsored (18)
Startups (2050)
State (1)
Stomach cancer (10)
Supply chain (31)
Tariffs (8)
The Weekly (5)
United States (16851)
Vaccines (593)
Venture capitalists (15)
Weight loss (100)
Women's health (19)
Worklife (2)
Date
Today (138)
Last 7 days (631)
Last 30 days (1974)
Last 365 days (24091)
2025 (7723)
2024 (25704)
2023 (29295)
2022 (37196)
2021 (39900)
2020 (37127)
2019 (29136)
2018 (22231)
2017 (21615)
2016 (19918)
2015 (24282)
2014 (17787)
2013 (13881)
2012 (14740)
2011 (15444)
2010 (14221)
Location
Africa (358)
Alabama (43)
Alaska (4)
Arizona (106)
Arkansas (9)
Asia (24091)
Australia (4163)
California (4538)
Canada (1388)
China (351)
Colorado (190)
Connecticut (202)
Delaware (103)
Europe (54450)
Florida (679)
Georgia (146)
Hawaii (1)
Idaho (31)
Illinois (308)
India (13)
Indiana (235)
Iowa (7)
Japan (134)
Kansas (80)
Kentucky (16)
Louisiana (8)
Maine (51)
Maryland (631)
Massachusetts (3476)
Michigan (170)
Minnesota (287)
Mississippi (1)
Missouri (66)
Montana (27)
Nebraska (18)
Nevada (55)
New Hampshire (34)
New Jersey (1255)
New Mexico (17)
New York (1307)
North Carolina (715)
North Dakota (6)
Northern California (2090)
Ohio (141)
Oklahoma (8)
Oregon (27)
Pennsylvania (957)
Puerto Rico (10)
Rhode Island (25)
South America (491)
South Carolina (9)
South Dakota (1)
Southern California (1655)
Tennessee (62)
Texas (631)
Utah (105)
Virginia (102)
Washington D.C. (22)
Washington State (475)
West Virginia (2)
Wisconsin (42)
436,068 Results for "immune design corporation".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
LifeMine Announces First Participant Dosed in First-in-human Phase 1 Clinical Trial of LIFE-001, Designed De Novo to Become a Field Dominating Immunosuppressive for Immune-mediated Disorders and Transplantation
April 8, 2025
·
4 min read
Press Releases
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma
December 12, 2024
·
6 min read
Startups
GSK-backed Ouro Launches With $120M to ‘Reset’ the Immune System
Ouro is planning to leverage T cell engagers to deplete B cells and “reset” the immune system to treat immune-mediated diseases.
January 10, 2025
·
2 min read
·
Tristan Manalac
Press Releases
AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update
March 13, 2025
·
14 min read
Genetown
Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer
Immuneering Corporation (Nasdaq: IMRX) today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for its lead clinical-stage program, IMM-1-104, for the treatment of patients with pancreatic ductal adenocarcinoma (PDAC) who have failed one line of treatment.
February 20, 2024
·
5 min read
Biotech Bay
Immune-Onc Therapeutics Announces Orphan Drug Designation Granted by US FDA for IO-202 (Anti-LILRB4) for the Treatment of Chronic Myelomonocytic Leukemia (CMML)
Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a clinical-stage biopharmaceutical company advancing novel therapies in immunology and oncology by targeting myeloid cell inhibitory receptors, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for IO-202 for the treatment of chronic myelomonocytic leukemia (CMML).
February 21, 2024
·
6 min read
Press Releases
Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer
October 15, 2024
·
6 min read
Press Releases
BioInvent Receives FDA Fast Track Designation for BI-1808 for the Treatment of Cutaneous T-cell Lymphoma
April 29, 2025
·
4 min read
Press Releases
Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP
April 21, 2025
·
5 min read
Press Releases
Synthetic Design Lab Emerges with $20M to Advance Next-Generation ADCs
April 24, 2025
·
5 min read
1 of 43,607
Next
